{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:29:06Z","timestamp":1787851746017,"version":"build-2784847793"},"reference-count":35,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2026,8,24]]},"DOI":"10.1080\/10428194.2026.2688561","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:18:43Z","timestamp":1783700323000},"page":"2116-2128","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison"],"prefix":"10.1080","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"first","affiliation":[{"name":"The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[{"name":"The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Zonder","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute, Wayne State University School of Medicine","place":["Detroit, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Hoffman","sequence":"additional","affiliation":[{"name":"University of Miami Health System","place":["Miami, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Yi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Garcia-Horton","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Fillbrunn","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjue","family":"Wang","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Mattera","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Inocencio","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxin","family":"Xu","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Harnett","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tito","family":"Roccia","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn S.","family":"Kroog","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Rodriguez Lorenc","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Knorr","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufei","family":"Ma","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Bumma","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center","place":["Columbus, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0141"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1355643"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01821"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061473"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2024.104265"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01008"},{"key":"e_1_3_4_8_1","unstructured":"European Medicines Agency. Oct 30. Lynozyfic\u2122 (linvoseltamab; Regeneron Pharmaceuticals Inc.) - EPAR Product Information. Revised 2025 Apr 23. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lynozyfic. Accessed 30 Oct 2025."},{"key":"e_1_3_4_9_1","unstructured":"US Food and Drug Administration. Oct 30. Lynozyfic\u2122 (linvoseltamab; Regeneron Pharmaceuticals Inc.) \u2013 Prescribing Information. Revised 02 Jul 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761400s000lbl.pdf. Accessed 2025 Oct 30."},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2313628"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)02304-8"},{"key":"e_1_3_4_16_1","volume-title":"P1979 Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed relapsed\/refractory multiple myeloma","author":"Lee HC","year":"2024","unstructured":"Lee HC, Jagannath S, Richter J, et\u00a0al. P1979 Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed relapsed\/refractory multiple myeloma. 2024. EHA Hybrid Congress, Madrid, Spain."},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.06.014"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208192"},{"key":"e_1_3_4_19_1","unstructured":"Phillippo D Ades T Dias S et\u00a0al. NICE DSU Technical Support Document 18: methods for population-adjusted indirect comparisons in submissions to NICE. 2016 Nov 19. https:\/\/research-information.bris.ac.uk\/ws\/portalfiles\/portal\/94868463\/Population_adjustment_TSD_FINAL.pdf. Accessed 2024 Nov 19."},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462319000333"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199733"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208192"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206951"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0155-7"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026212"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000975152.94267.34"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.03.013"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1267"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2488"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208776"},{"key":"e_1_3_4_32_1","unstructured":"US Food and Drug Administration. Project Optimus - Reforming the dose optimization and dose selection paradigm in oncology. https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-optimus. Accessed 2024 Nov 19."},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-025-00333-7"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0932"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.4065\/83.10.1142"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2026.2688561","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/10428194.2026.2688561","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2026.2688561","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:07:47Z","timestamp":1787850467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2026.2688561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,8,24]]}},"alternative-id":["10.1080\/10428194.2026.2688561"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2026.2688561","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-01-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}